Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1271418
Max Phase: Preclinical
Molecular Formula: C27H34F3N5O
Molecular Weight: 501.60
Molecule Type: Small molecule
Associated Items:
ID: ALA1271418
Max Phase: Preclinical
Molecular Formula: C27H34F3N5O
Molecular Weight: 501.60
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1ncnc(C)c1C(=O)N1C[C@H]2CN(CCC(c3ccccc3)C3CN(CC(F)(F)F)C3)C[C@H]2C1
Standard InChI: InChI=1S/C27H34F3N5O/c1-18-25(19(2)32-17-31-18)26(36)35-14-21-10-33(11-22(21)15-35)9-8-24(20-6-4-3-5-7-20)23-12-34(13-23)16-27(28,29)30/h3-7,17,21-24H,8-16H2,1-2H3/t21-,22+,24?
Standard InChI Key: KHJSAQHDNAQQMO-RIKCKFAHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 501.60 | Molecular Weight (Monoisotopic): 501.2715 | AlogP: 3.77 | #Rotatable Bonds: 7 |
Polar Surface Area: 52.57 | Molecular Species: BASE | HBA: 5 | HBD: 0 |
#RO5 Violations: 1 | HBA (Lipinski): 6 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: 9.86 | CX LogP: 2.09 | CX LogD: -0.34 |
Aromatic Rings: 2 | Heavy Atoms: 36 | QED Weighted: 0.58 | Np Likeness Score: -0.89 |
1. Wanner J, Chen L, Lemoine RC, Kondru R, Jekle A, Heilek G, deRosier A, Ji C, Berry PW, Rotstein DM.. (2010) Evaluation of amide replacements in CCR5 antagonists as a means to increase intrinsic permeability. Part 2: SAR optimization and pharmacokinetic profile of a homologous azacyle series., 20 (22): [PMID:20855212] [10.1016/j.bmcl.2010.08.118] |
Source(1):